[Antithrombotic activity of low molecular weight heparin (enoxaparin) during hemodialysis in patients with terminal kidney failure].
The aim of the study was to evaluate the efficacy of low molecular weight heparine (enoxaparin) in comparison to heparin during haemodialysis (HD) in prevention of blood clotting chestry extracorporeal circulation. Enoxaparin (Clexan, Rhone-Poulenc Rorer, in syringes, 20 mg) was evaluated in 42 patients with end stage renal failure treated with HD. In the first part of study heparine and in the second part enoxaparin given into arterial lines were evaluated during 6 following HD with the same type of dialysator. Clotting of extracorporeal circulation and bleeding time from the needle site after HD were evaluated. Activated partial thromboplastin time (APTT) before, after 1 hour of HD and after HD during heparine and enoxaparin were measured. There was advantage of enoxaparin in 23 patients when compared to heparine. It was depended on the reduction of number of injections of enoxaparin when compared to heparine (22 patients have received heparine in 2 or more doses when only 5 patients have received enoxaparin in 2 doses) on the reduction of clotting events in extracorporeal circulation (16 events during heparine treatment -6.3% of all HD and 5 events during enoxaparin treatment -2.0% of all HD), and on the shortening of the bleeding time from the needle site after HD (5.9 +/- 3.4 min. during heparin and 4.5 +/- 1.6 min. during enoxaparin treatment; p < 0.02). Increase of APTT after 1 hour of HD when compared to the value from before HD was significantly lower during enoxaparin than heparine therapy (1.73 +/- 0.4 and 2.55 +/- 0.91 respectively; p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Przedlacki
J
J
I Kliniki Chorób Wewnetrznych Akademii Medycznej w Warszawie.
Bogdańska-Straszyńska
B
B
Sawicka
B
B
Włodarczyk
D
D
Sladowska
B
B
Ajewski
M
M
Wasiak
K
K
Gellert
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D001780:Blood Coagulation Tests; D017984:Enoxaparin / Q000627:therapeutic use*; D005112:Extracorporeal Circulation; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013927:Thrombosis / Q000517:prevention & control*
D017984:Enoxaparin; D006493:Heparin
Przeciwzakrzepowe działanie niskoczasteczkowej heparyny (enoksaparyny) w czasie hemodializy u pacjentów ze schyłkowa niewydolnościa nerek.